Q3 EPS Estimate for Ensysce Biosciences Lowered by Analyst

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Research analysts at Zacks Small Cap reduced their Q3 2025 earnings per share (EPS) estimates for Ensysce Biosciences in a report released on Thursday, August 14th. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings per share of ($0.76) for the quarter, down from their prior estimate of ($0.72). The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($8.33) per share. Zacks Small Cap also issued estimates for Ensysce Biosciences’ Q4 2025 earnings at ($0.74) EPS, FY2025 earnings at ($3.68) EPS and FY2026 earnings at $2.58 EPS.

Separately, Wall Street Zen downgraded Ensysce Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, July 12th.

Ensysce Biosciences Stock Performance

Shares of ENSC stock opened at $2.05 on Monday. The business’s fifty day moving average is $2.16 and its 200 day moving average is $3.03. Ensysce Biosciences has a 52-week low of $1.62 and a 52-week high of $14.67. The company has a market capitalization of $6.09 million, a PE ratio of -0.51 and a beta of 1.00.

Ensysce Biosciences (NASDAQ:ENSC) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.23. Ensysce Biosciences had a negative return on equity of 167.23% and a negative net margin of 88.76%. The company had revenue of $1.37 million for the quarter, compared to the consensus estimate of $0.67 million.

Institutional Investors Weigh In On Ensysce Biosciences

An institutional investor recently raised its position in Ensysce Biosciences stock. Adage Capital Partners GP L.L.C. raised its position in shares of Ensysce Biosciences, Inc. (NASDAQ:ENSC) by 49.4% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 74,711 shares of the company’s stock after purchasing an additional 24,711 shares during the period. Adage Capital Partners GP L.L.C. owned approximately 3.15% of Ensysce Biosciences worth $191,000 at the end of the most recent reporting period. 5.63% of the stock is owned by hedge funds and other institutional investors.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.